These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 20539145)

  • 1. The patients' and consumers' working party at the European Medicines Agency: a model of interaction between patients, consumers, and medicines regulatory authorities.
    Moulon I; Dedes N
    J Ambul Care Manage; 2010; 33(3):190-7. PubMed ID: 20539145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The innovative medicines initiative: a European response to the innovation challenge.
    Goldman M
    Clin Pharmacol Ther; 2012 Mar; 91(3):418-25. PubMed ID: 22318619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The European Medicines Agency: an overview of its mission, responsibilities, and recent initiatives in cancer drug regulation.
    Pignatti F; Gravanis I; Herold R; Vamvakas S; Jonsson B; Marty M
    Clin Cancer Res; 2011 Aug; 17(16):5220-5. PubMed ID: 21844037
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granting marketing authorisation for medicines in South East European countries: the point of view of the authority.
    Tomić S; Sucić AF; Martinac AI
    Regul Toxicol Pharmacol; 2010; 57(2-3):325-32. PubMed ID: 20385190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Provision of information on regulatory authorities' websites.
    Vitry A; Lexchin J; Sasich L; Dupin-Spriet T; Reed T; Bertele V; Garattini S; Toop L; Hurley E
    Intern Med J; 2008 Jul; 38(7):559-67. PubMed ID: 18336542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory review: How do agencies ensure the quality of decision making?
    Liberti L; McAuslane N; Patel P; Breckenridge A; Eichler HG; Peterson R
    Clin Pharmacol Ther; 2013 Sep; 94(3):305-8. PubMed ID: 23963218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. European Medicines Agency tightens rules on conflict of interest.
    Cohen D
    BMJ; 2010 Oct; 341():c5902. PubMed ID: 20959306
    [No Abstract]   [Full Text] [Related]  

  • 8. Consumers' views on generic medicines: a review of the literature.
    Hassali MA; Shafie AA; Jamshed S; Ibrahim MI; Awaisu A
    Int J Pharm Pract; 2009 Apr; 17(2):79-88. PubMed ID: 20214255
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products.
    Ceci A; Felisi M; Catapano M; Baiardi P; Cipollina L; Ravera S; Bagnulo S; Reggio S; Rondini G
    Eur J Clin Pharmacol; 2002 Nov; 58(8):495-500. PubMed ID: 12451425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A report by a working party 1975. Council of Europe European Public Health Community. Abuse of Medicines. I. Self medication.
    Drug Intell Clin Pharm; 1976 Jan; 10(1):16-33. PubMed ID: 10316503
    [No Abstract]   [Full Text] [Related]  

  • 11. Data Integrity-A Study of Current Regulatory Thinking and Action.
    Shafiei N; De Montardy R; Rivera-Martinez E
    PDA J Pharm Sci Technol; 2015; 69(6):762-70. PubMed ID: 26659106
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Industrial interests versus public health: the gap is growing.
    Prescrire Int; 2004 Apr; 13(70):71-6. PubMed ID: 15148985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early communication of drug safety concerns: a feasibility study on enhancing interaction between the pharmaceutical industry and regulators.
    Swain E; Morgan S; Brewster W; Kauser S
    Pharmacoepidemiol Drug Saf; 2010 Mar; 19(3):232-7. PubMed ID: 20033909
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Europe and medicines: role of the EMEA].
    Sauer F
    Ann Pharm Fr; 2000 Jul; 58(4):278-85. PubMed ID: 10915977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Government regulation of pricing and reimbursement of prescription medicines: results of a recent multi-country review.
    Kingham R; Wheeler J
    Food Drug Law J; 2009; 64(1):101-14. PubMed ID: 19998574
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A report by a working party 1975. Council of Europe European Public Health Community. Abuse of medicines. II. Prescription medicines.
    Drug Intell Clin Pharm; 1976 Feb; 10(2):94-110. PubMed ID: 10316507
    [No Abstract]   [Full Text] [Related]  

  • 17. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
    Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New safe medicines faster: A proposal for a key action within the European union's 6th framework programme.
    Bjerrum OJ
    Pharmacol Toxicol; 2000; 86 Suppl 1():23-6. PubMed ID: 10905750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory pathways for vaccines for developing countries.
    Milstien J; Belgharbi L
    Bull World Health Organ; 2004 Feb; 82(2):128-33. PubMed ID: 15042235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fostering a strategic alliance between patients' associations and health care professionals.
    Mosconi P; Colombo C
    J Ambul Care Manage; 2010; 33(3):223-30. PubMed ID: 20539149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.